Throughout the last three months, 7 analysts have evaluated GE HealthCare Techs (NASDAQ:GEHC), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 2 | 0 | 1 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 1 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $91.14, along with a high estimate of $105.00 and a low estimate of $77.00. This current average reflects an increase of 6.15% from the previous average price target of $85.86.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of GE HealthCare Techs’s perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Key Insights:
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GE HealthCare Techs’s market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on GE HealthCare Techs analyst ratings.
Unveiling the Story Behind GE HealthCare Techs
A Deep Dive into GE HealthCare Techs’s Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: GE HealthCare Techs’s remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 5.78%. This signifies a substantial increase in the company’s top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: GE HealthCare Techs’s net margin surpasses industry standards, highlighting the company’s exceptional financial performance. With an impressive 8.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): GE HealthCare Techs’s financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): GE HealthCare Techs’s ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.25%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.08, GE HealthCare Techs faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish “analyst ratings” for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
link